Clopidogrel, sold as the brandname Plavix among others, is an antiplatelet medication that is used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent. It is taken by mouth.
Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are in clinical trials. As a result, the drug did not face much competition and has taken over the global market, with its array of application constantly expanding.
The substantial and high-level evidence gathered over the years support the use of Clopidogrel for reduction of mortality and morbidity patients with acute coronary syndrome, myocardial infarction, and a number of other indications. As a result, the drug has developed a formidable presence in the global market over the years. Moreover, the drug’s relative ease of use, low rate of incidence of adverse reactions, and good tolerability have made it the de-facto antiplatelet agent for the reduction of atherosclerotic events in patients.
These factors have helped the global Clopidogrel market to tread along an excellent growth path in the past few years and the market is expected to embark upon a healthy growth path in the next few years as well. However, the overall profitability of the market has reduced to a certain extent owing to entry of a number of generic products post the patent expiry of Clopidogrel manufacture in 2013. Nevertheless, the vast pool of patients prescribed Clopidogrel on an annual basis across the globe will allow market players excellent growth prospects in the next few years.
The global Clopidogrel market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Clopidogrel volume and value at global level, regional level and company level. From a global perspective, this report represents overall Clopidogrel market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Sanofi (France)
Shenzhen Salubris Pharmaceuticals (China)
Lepu Medical Technology (China)
...
Segment by Regions
North America
Europe
China
Japan
Summary: Get latest Market Research Reports on Clopidogrel. Industry analysis & Market Report on Clopidogrel is a syndicated market report, published as Global Clopidogrel Market Research Report 2019. It is complete Research Study and Industry Analysis of Clopidogrel market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.